

activity at discrete time periods. The contribution of energy expenditure to body weight maintenance during activation is unclear. These results will inform not only the neurobiological underpinnings of AN but also provide an insight into the mechanisms of reward pathways relevant to feeding and weight loss.

<https://doi.org/10.1016/j.orcp.2016.10.074>

74

Harnessing the sun to halt obesity: Vitamin D, nitric oxide and brown adipose tissue



Shelley Gorman^{1,*}, Sian Geldenhuys¹, Naomi Fleury¹, Martin Feelisch², Richard Weller³, Vance Matthews⁴

¹ Telethon Kids Institute, Subiaco, WA, Australia

² University of Southampton, Southampton, United Kingdom

³ University of Edinburgh, Edinburgh, Scotland, United Kingdom

⁴ Harry Perkins Institute of Medical Research, Perth, Australia

The role of vitamin D in curtailing the development of obesity and comorbidities like the metabolic syndrome (MetS) and type-2 diabetes has received much attention recently. However, clinical trials have failed to conclusively demonstrate the benefits of vitamin D supplementation. In most studies, serum 25-hydroxyvitamin D (25(OH)D) decreases with increasing BMI above normal weight. These low 25(OH)D levels may also be a proxy for reduced exposure to sunlight-derived ultraviolet radiation (UVR). We have found that frequent skin exposure to a low non-burning dose of UVR reduced weight gain in C57Bl/6 male mice fed a high fat diet. Ongoing exposure to UVR also significantly suppressed glucose intolerance, insulin resistance, signs of non-alcoholic fatty-liver disease and serum levels of fasting insulin and glucose. These findings were independent of circulating 25(OH)D, and most could not be mimicked by vitamin D supplementation. We are now starting to characterise the effects of biological mediators induced by exposure to UVR, such as nitric oxide, and their potential to prevent obesity in already 'overweight' mice, as well as the potential involvement of brown adipose tissue using the uncoupled protein-1 luciferase transgenic mouse ('Thermomouse'), in which thermogenesis in brown adipose tissue can be tracked *in vivo*. Our studies suggest that UVR

(sunlight exposure) may be an effective means of suppressing the development of obesity and MetS through mechanisms that are partially dependent on nitric oxide, and other novel UVR-induced mediators.

<https://doi.org/10.1016/j.orcp.2016.10.075>

75

Investigating the molecular basis and therapeutic potential of the heme oxygenase-1 (HO-751) – Adiponectin axis



Mengliu Yang, Johanna Barclay, Jon Whitehead*

Mater Research Institute, University of Queensland, Brisbane, QLD, Australia

Adiponectin is a beneficial hormone produced primarily by adipocytes. Paradoxically, circulating adiponectin levels are reduced in the context of obesity and associated diseases. This hypoadiponectinemia is implicated in the aetiology of obesity-related cardiometabolic diseases making therapeutic strategies to increase adiponectin attractive. An emerging body of literature suggests that increasing heme oxygenase 1 (HO-1) may increase adiponectin levels, prompting the proposal of an 'HO-1 – adiponectin axis'. We have performed a series of investigations to explore this possibility.

Using two *in vitro* models of human adipocytes, combined with a comprehensive array of pharmaceutical (cobalt protoporphyrin (CoPP) or hemin) and genetic modulators of HO-1, we found that neither acute¹ nor chronic induction of HO-1 results in increased adiponectin production. However, in a mouse model of diet-induced obesity we observed that systemic induction of HO-1 with CoPP increased circulating adiponectin levels and this was concurrent with decreased food intake, body weight gain and adipocyte size as well as enhanced insulin sensitivity and reduced liver steatosis. Importantly only the effect on adiponectin was blunted when mice were co-treated with an inhibitor of HO-1 activity (SnMP) [1].

Taken together, our *in vitro* and *in vivo* observations suggest that CoPP increases circulating adiponectin levels in an indirect manner that is, at least partly, dependent on HO-1 activity. Furthermore, our *in vivo* studies indicate that systemic treatment with CoPP results in reduced food intake and improvements in a range of metabolic